Search Results - zhiqiang+an

8 Results Sort By:
Monoclonal antibodies against human endotrophin for therapeutic and diagnostic use.
Background Studies have shown that endotrophin, the carboxy-terminal cleavage product of the COL6α3 chain, has potent effects on transformed mammary ductal epithelial cells in rodents. It is abundantly expressed in adipose tissue and is a chemoattractant for macrophages, exerts effects on endothelial cells and enhances the progression through...
Published: 2/8/2024   |   Inventor(s): Zhiqiang An, Ningyan Zhang, Philipp Scherer
Keywords(s):  
Category(s): Biologics, Oncology, Therapeutics
Monoclonal Antibodies Binding to Transferrin Receptor (TfR) for Therapeutic Protein Delivery across Blood-Brain Barrier
Blood-brain barrier (BBB) limits brain entry and is one of the major hurdles in developing antibody and protein-based therapeutics for central nervous system (CNS) diseases. UTHealth researchers identified and engineered monoclonal antibodies binding to transferrin receptor (TfR) but not affecting transferrin (Tf) binding to TfR. An engineered monovalent...
Published: 12/19/2023   |   Inventor(s): Zhiqiang An
Keywords(s):  
Category(s): Drug Delivery, Therapeutics
TREM2 Monoclonal Antibody for Therapeutic and Diagnostic Use
Triggering Receptor Expressed on Myeloid cells 2 (TREM2) plays a key regulatory role in Alzheimer’s disease (AD) by controlling microglia activation and metabolic activities in brain tissues. Previous studies in rodent models of AD have shown that mice with increased TREM2 expression have reduced amyloid pathology. UTHealth inventors created and...
Published: 12/19/2023   |   Inventor(s): Zhiqiang An
Keywords(s):  
Category(s): Therapeutics, Oncology, Diagnostics
EGFL6 Specific Monoclonal Antibodies for Cancer Diagnostic and Therapeutic Use
Human epidermal growth factor (EGF)-like domain multiple 6 (EGFL6) was discovered in tumors and fetal tissues. Upregulated expression of EGFL6 was found in a variety of cancer cell types, such as ovarian cancer and lung cancer. Unlike VEGF, which was expressed in ovarian cancer tissues and in healing wounds, EGFL6 was expressed mainly in tumor-associated...
Published: 12/19/2023   |   Inventor(s): Zhiqiang An
Keywords(s):  
Category(s): Biologics, Therapeutics
Monoclonal Antibodies Against Oncostatin M Receptor (OSMR) for Therapeutic and Diagnostic Use
­Researchers from UTHealth and The Medical College of Wisconsin have collaborated to reveal the role of OSMR in promoting ovarian cancer cell proliferation and metastasis through activation of STAT3 signaling, as well as illuminated the preclinical efficacy of antibody-based OSMR targeting for ovarian cancer treatment. More particularly, researchers...
Published: 9/27/2023   |   Inventor(s): Zhiqiang An
Keywords(s):  
Category(s): Diagnostics, Therapeutics, Biologics, Oncology
Monoclonal Antibodies Against Chitinase 3-like-1 (Chi3l1) for Therapeutic and Diagnostic Use
­Researchers at UTHealth have unveiled a critical role of Chi3l1 in hepatic platelet recruitment during acetaminophen (APAP)-induced liver injury (AILI) using murine models of AILI and concanavalin A (Con A)-induced hepatitis. Significantly, they have developed anti-Chi3l1 monoclonal antibodies and demonstrated the feasibility of targeting CHI3L1...
Published: 8/15/2023   |   Inventor(s): Zhiqiang An, Changqing (Cynthia) Ju
Keywords(s):  
Category(s): Biologics, Therapeutics, Oncology
Monoclonal antibodies against human and mouse leptin for therapeutic and diagnostic use.
BackgroundLeptin is a hormone produced by adipocytes and is elevated in obesity. The congenital lack of leptin results in obesity and the metabolism field widely accepts the concept. Upon cloning of the leptin gene, the original hope was that leptin would act as a break for further food intake and a trigger to increase energy expenditure. The hope was...
Published: 2/8/2024   |   Inventor(s): Zhiqiang An, Philipp Scherer, Ningyan Zhang
Keywords(s):  
Category(s): Biologics, Oncology, Therapeutics, Metabolism
HER3 specific monoclonal antibodies for diagnosis and therapeutic use
BackgroundHER-3 is a receptor in the tyrosine kinase family that is a key oncogenic protein in breast cancer as well as other cancers. HER-3 is centrally involved in signaling leading to tumor growth and has been implicated in resistance to cancer treatments, making it an attractive target for cancer therapies. Several drugs, including some in clinical...
Published: 8/15/2023   |   Inventor(s): Zhiqiang An, Ningyan Zhang
Keywords(s):  
Category(s): Therapeutics, Diagnostics
© 2024. All Rights Reserved. Powered by Inteum